Last reviewed · How we verify
NCT07236320
Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC
NA trial testing Neoadjuvant immunochemotherapy in Esophageal Squamous Cell Carcinoma (ESCC) in 200 participants. Completed in 28 February 2025.
31 March 2022
Quick facts
| Lead sponsor | Yongtao Han |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 200 |
| Start date | 1 March 2018 |
| Primary completion | 31 March 2022 |
| Estimated completion | 28 February 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Neoadjuvant immunochemotherapy — full drug profile →
- Neoadjuvant Chemoradiotherapy — full drug profile →
Conditions studied
- Esophageal Squamous Cell Carcinoma (ESCC) — all drugs for Esophageal Squamous Cell Carcinoma (ESCC) →
Sponsor
Yongtao Han — full company profile →
Who can join
Adults 18 to 80, any sex, with Esophageal Squamous Cell Carcinoma (ESCC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This retrospective real-world study aimed to compare neoadjuvant immunochemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT) followed by esophagectomy in patients with locally advanced esophageal squamous cell carcinoma (ESCC). A total of 203 consecutive patients treated at Sichuan Cancer Hospital between March 2018 and March 2022 were analyzed (NICT: 59; NCRT: 144). The primary endpoints were overall survival (OS) and disease-free survival (DFS); secondary endpoints included pathological complete response (pCR), tumor regression grade (TRG), and R0 resection rate. After inverse probability of treatment weighting adjustment, baseline characteristics were balanced between groups. Both groups achieved comparable long-term OS and DFS, while NCRT showed higher rates of local pathological response. Exploratory subgroup analysis suggested that patients achieving pCR after NICT might have superior survival outcomes. The study indicates that NICT provides similar long-term survival compared to NCRT and may offer immunologic advantages for selected responders, warranting further validation in prospective multicenter trials.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07236320
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Neoadjuvant immunochemotherapy
Trials testing the same drug.
- NCT07086469 — Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unres · Phase 2 · recruiting
- NCT07003620 — Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial · Phase 2 · recruiting
- NCT05974007 — Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC · recruiting
- NCT04280822 — Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma · Phase 3 · recruiting
Other recruiting trials for Esophageal Squamous Cell Carcinoma (ESCC)
Currently open trials in the same condition.
- NCT07339488 — Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal · Phase 2 · active not recruiting
- NCT07039162 — Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma · Phase 2 · recruiting
- NCT07142421 — A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophage · Phase 2 · active not recruiting
- NCT07317609 — Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurg · Phase 1 · recruiting
- NCT07359417 — MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma · Phase 1 · recruiting
Other Yongtao Han trials
Trials by the same sponsor.
- NCT06169930 — Development and Validation of a Survival Prediction Model for Esophageal Cancer Patients After Esophagectomy · completed
- NCT05570487 — RESECTED LYMPH NODES AND SURVIVAL OF PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA: AN OBSERVATIONAL STUDY · unknown
- NCT05617352 — The Impact of Two-field or Three-field Lymphadenectomy on Overall Survival in Middle and Lower Thoracic Esophageal Squam · completed
- NCT05604664 — Clinical Value and Efficacy Index of Lymphadenectomy for Thoracic Escc · completed
- NCT06775652 — Neoadjuvant Chemoradiotherapy Plus Surgery vs. Surgery Plus Adjuvant Therapy for ESCC · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07236320 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yongtao Han
- Last refreshed: 19 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07236320.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing